Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies
Part of paid clinical trials in Fort Smith, Arkansas.
- Sponsor
- Elephas
- Study ID
- NCT07327489
- Status
- Recruiting
Conditions
- Advanced Solid Tumors Cancer
- Bladder Cancer
- Cancer
- Colorectal Cancer
- DMMR Colorectal Cancer
- Endometrial Cancer
- Head and Neck Cancer
- Immunotherapy
- Kidney Cancer
- Liver Cancer
- MSI-H Colorectal Cancer
- Melanoma (Skin Cancer)
- NSCLC (Non-small-cell Lung Cancer)
- Skin Cancer
- TNBC, Triple Negative Breast Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Biopsy — PROCEDURESubjects must be clinically able, at investigator discretion, to undergo additional biopsy passes during their biopsy. Biopsy specimen(s) will be obtained during a standard of care (SOC) procedure. If a subject receives a subsequent SOC biopsy for clinical diagnosis purposes, additional sample(s) may be collected and sent to the Sponsor.
Study Details
This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up for suspected or confirmed cancer.
Key Dates
- Start date
- Apr 14, 2025
- Status verified
- Jan 2026
- Primary completion
- Apr 30, 2035
- Completion
- Apr 30, 2038
Study Design
- Enrollment
- 2,000 participants (estimated)
Arms
- Arm: Study PopulationAdults aged 18 years or older, who are able and willing to provide written informed consent, have a suspected or confirmed cancer diagnosis and will be undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up.
Primary Outcome Measure
Predicting In-Vivo Clinical Response to Immune Checkpoint Inhibitors & Researching Mechanisms of Tumor Cutting and Imaging [ Time Frame: Study duration is approximately 36 months from enrollment to end of study. ]
Locations (8)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mercy Hospital - FTS | Fort Smith | Arkansas | 72903 | Aswanth Reddy, MD (PRINCIPAL_INVESTIGATOR) |
| Frederick Health Hospital | Frederick | Maryland | 21702 | Heather Chalfin, MD (PRINCIPAL_INVESTIGATOR) |
| Mercy Hospital - SPG | Springfield | Missouri | 65804 | Mohan Tummala, MD (PRINCIPAL_INVESTIGATOR) |
| Mercy Hospital - South | St Louis | Missouri | 63128 | Yifan Tu (PRINCIPAL_INVESTIGATOR) |
| Mercy Hospital -STL | St Louis | Missouri | 63141 | Nancy Umbeck Bethany Sleckman (PRINCIPAL_INVESTIGATOR) |
| Mercy Hospital - OKC | Oklahoma City | Oklahoma | 73120 | Carla Kurkjian (PRINCIPAL_INVESTIGATOR) |
| JPS Health Network | Forth Worth | Texas | 76104 | Paras Patel (PRINCIPAL_INVESTIGATOR) |
| Baylor Scott and White Biorepository | Temple | Texas | 76508 | Mathew Bower, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Fort Smith, AR
By condition
By specialty
Related Studies
- Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant DisordersRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Evaluation for NCI Surgery Branch Clinical Research ProtocolsRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Evaluation of Late Effects and Natural History of Disease in Patients Treated With RadiotherapyRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant DiseaseRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland